Table 1.
Demographic and clinical features of Turkish patients with rheumatoid arthritis
| Rheumatoid Artritis (n=93) | |
|---|---|
| Age (years) | 60.0±8.9 |
| Gender (male/female) | 6/87 |
| Biological Therapy | 34.4% |
| Disease Duration (months) | 55.8±28.0 |
| Steroid Dose (mg) | 8.3±8.0 |
| DAS28-ESR | 3.9±1.0 |
| Rheumatoid Factor (RF) | |
| • RF positivity n (%) | 38 (40.9%) |
| • RF titer* | 74.1 (2.2–66.2) |
| • RF titer in positive patients* | 174.7 (53.2–208.5) |
| ACPA | |
| • ACPA positivity n (%) | 45 (48.4%) |
| • ACPA titer* | 49.9 (0.5–84.3) |
| • ACPA titer in positive patients* | 102.3 (25–200) |
| T-score | |
| • Lumbar | −2.4±0.9 |
| • Femoral neck | 1.8±1.0 |
| • Total hip | −0.9±1.2 |
| Z-score | |
| • Lumbar | −1.0±1.1 |
| • Total femur | −0.9±1.2 |
| • Femoral neck | −0.3±1.0 |
*
median (25%–75%)
DAS28-ESR: disease activity score 28-erythrocyte sedimentation rate; ACPA: anti-citrullinated protein antibody